SCHEMBL2272706

SCHEMBL2272706

COc1ccc(Oc2ccc(C(=O)O)c(NC(=O)c3ccccc3)c2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.67
KMT2A Q03164 3/20 0.67
PKM P14618 2/20 0.67
NPSR1 Q6W5P4 1/20 0.67
PGR P06401 1/20 0.61
KCNK2 O95069 1/20 0.60
KCNK10 P57789 1/20 0.60
PYGM P11217 2/20 0.60
MAPT P10636 2/20 0.59
F10 P00742 2/20 0.58
PYGL P06737 1/20 0.57
NPC1 O15118 1/20 0.57
RAB9A P51151 1/20 0.57
GRIK1 P39086 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
AKR1C3 P42330 1/20 0.56
AKR1C2 P52895 1/20 0.56
KCNK9 Q9NPC2 1/20 0.56
SERPINE1 P05121 1/20 0.55
HDAC2 Q92769 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2271007 0.96 MEN1 (0.69) MEN1KMT2APKMNPSR1PGR
SCHEMBL2272040 0.92 PGR (0.69) MEN1KMT2APKMNPSR1PGR
SCHEMBL2935687 0.92 MEN1 (0.69) MEN1KMT2APKMNPSR1KCNK2
SCHEMBL2271588 0.92 SERPINE1 (0.64) MEN1KMT2APKMPGRPYGM
SCHEMBL2271177 0.91 PYGM (0.72) MEN1KMT2APGRPYGMNPC1
SCHEMBL2273044 0.90 CYP2C9 (0.61) MEN1KMT2APKMNPSR1PYGM
SCHEMBL2274898 0.88 SERPINE1 (0.60) MEN1KMT2APKMPGRPYGM
SCHEMBL2275393 0.87 HDAC2 (0.73) MEN1KMT2APKMNPSR1KCNK2
SCHEMBL2274811 0.87 PYGM (0.57) MEN1KMT2APKMPGRKCNK2
SCHEMBL2272347 0.87 SERPINE1 (0.69) MEN1KMT2APKMNPSR1PYGM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 MEN1 3105/4885KMT2A 1669/4885PKM 2367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.